Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq:ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer